171 related articles for article (PubMed ID: 36192391)
1. DHRS2 inhibits cell growth and metastasis in ovarian cancer by downregulation of CHKα to disrupt choline metabolism.
Li Z; Tan Y; Li X; Quan J; Bode AM; Cao Y; Luo X
Cell Death Dis; 2022 Oct; 13(10):845. PubMed ID: 36192391
[TBL] [Abstract][Full Text] [Related]
2. Emerging roles of dehydrogenase/reductase member 2 (DHRS2) in the pathology of disease.
Li Z; Liu H; Bode A; Luo X
Eur J Pharmacol; 2021 May; 898():173972. PubMed ID: 33652058
[TBL] [Abstract][Full Text] [Related]
3. DHRS2 mediates cell growth inhibition induced by Trichothecin in nasopharyngeal carcinoma.
Luo X; Li N; Zhao X; Liao C; Ye R; Cheng C; Xu Z; Quan J; Liu J; Cao Y
J Exp Clin Cancer Res; 2019 Jul; 38(1):300. PubMed ID: 31291971
[TBL] [Abstract][Full Text] [Related]
4. Decreased DHRS2 expression is associated with HDACi resistance and poor prognosis in ovarian cancer.
Han Y; Wang Z; Sun S; Zhang Z; Liu J; Jin X; Wu P; Ji T; Ding W; Wang B; Gao Q
Epigenetics; 2020; 15(1-2):122-133. PubMed ID: 31423895
[TBL] [Abstract][Full Text] [Related]
5. Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer.
Granata A; Nicoletti R; Tinaglia V; De Cecco L; Pisanu ME; Ricci A; Podo F; Canevari S; Iorio E; Bagnoli M; Mezzanzanica D
Br J Cancer; 2014 Jan; 110(2):330-40. PubMed ID: 24281000
[TBL] [Abstract][Full Text] [Related]
6. Molecular Effects of Doxorubicin on Choline Metabolism in Breast Cancer.
Cheng M; Rizwan A; Jiang L; Bhujwalla ZM; Glunde K
Neoplasia; 2017 Aug; 19(8):617-627. PubMed ID: 28654865
[TBL] [Abstract][Full Text] [Related]
7. Interplay of choline metabolites and genes in patient-derived breast cancer xenografts.
Grinde MT; Skrbo N; Moestue SA; Rødland EA; Borgan E; Kristian A; Sitter B; Bathen TF; Børresen-Dale AL; Mælandsmo GM; Engebraaten O; Sørlie T; Marangoni E; Gribbestad IS
Breast Cancer Res; 2014 Jan; 16(1):R5. PubMed ID: 24447408
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the dehydrogenase-reductase DHRS2 and its involvement in histone deacetylase inhibition in urological malignancies.
Müller MR; Burmeister A; Skowron MA; Stephan A; Söhngen C; Wollnitzke P; Petzsch P; Alves Avelar LA; Kurz T; Köhrer K; Levkau B; Nettersheim D
Exp Cell Res; 2024 Jun; 439(1):114055. PubMed ID: 38704080
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic regulation of DHRS2 by SUV420H2 inhibits cell apoptosis in renal cell carcinoma.
Ryu TY; Lee J; Kang Y; Son MY; Kim DS; Lee YS; Kim MY; Cho HS
Biochem Biophys Res Commun; 2023 Jun; 663():41-46. PubMed ID: 37119764
[TBL] [Abstract][Full Text] [Related]
10. DHRS2 inhibits cell growth and motility in esophageal squamous cell carcinoma.
Zhou Y; Wang L; Ban X; Zeng T; Zhu Y; Li M; Guan XY; Li Y
Oncogene; 2018 Feb; 37(8):1086-1094. PubMed ID: 29106393
[TBL] [Abstract][Full Text] [Related]
11. Choline phosphorylation and regulation of transcription of choline kinase α in hypoxia.
Bansal A; Harris RA; DeGrado TR
J Lipid Res; 2012 Jan; 53(1):149-57. PubMed ID: 22025560
[TBL] [Abstract][Full Text] [Related]
12. The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.
Al-Saffar NM; Jackson LE; Raynaud FI; Clarke PA; Ramírez de Molina A; Lacal JC; Workman P; Leach MO
Cancer Res; 2010 Jul; 70(13):5507-17. PubMed ID: 20551061
[TBL] [Abstract][Full Text] [Related]
13. Metabolic profiling of transgenic adenocarcinoma of mouse prostate (TRAMP) tissue by 1H-NMR analysis: evidence for unusual phospholipid metabolism.
Teichert F; Verschoyle RD; Greaves P; Edwards RE; Teahan O; Jones DJ; Wilson ID; Farmer PB; Steward WP; Gant TW; Gescher AJ; Keun HC
Prostate; 2008 Jul; 68(10):1035-47. PubMed ID: 18459103
[TBL] [Abstract][Full Text] [Related]
14. The moonlighting function of glycolytic enzyme enolase-1 promotes choline phospholipid metabolism and tumor cell proliferation.
Ma Q; Jiang H; Ma L; Zhao G; Xu Q; Guo D; He N; Liu H; Meng Z; Liu J; Zhu L; Lin Q; Wu X; Li M; Luo S; Fang J; Lu Z
Proc Natl Acad Sci U S A; 2023 Apr; 120(15):e2209435120. PubMed ID: 37011206
[TBL] [Abstract][Full Text] [Related]
15. Global metabolic profile identifies choline kinase alpha as a key regulator of glutathione-dependent antioxidant cell defense in ovarian carcinoma.
Granata A; Nicoletti R; Perego P; Iorio E; Krishnamachary B; Benigni F; Ricci A; Podo F; Bhujwalla ZM; Canevari S; Bagnoli M; Mezzanzanica D
Oncotarget; 2015 May; 6(13):11216-30. PubMed ID: 25796169
[TBL] [Abstract][Full Text] [Related]
16. A novel small molecule antagonist of choline kinase-α that simultaneously suppresses MAPK and PI3K/AKT signaling.
Clem BF; Clem AL; Yalcin A; Goswami U; Arumugam S; Telang S; Trent JO; Chesney J
Oncogene; 2011 Jul; 30(30):3370-80. PubMed ID: 21423211
[TBL] [Abstract][Full Text] [Related]
17. Regulation of Akt(ser473) phosphorylation by choline kinase in breast carcinoma cells.
Chua BT; Gallego-Ortega D; Ramirez de Molina A; Ullrich A; Lacal JC; Downward J
Mol Cancer; 2009 Dec; 8():131. PubMed ID: 20042122
[TBL] [Abstract][Full Text] [Related]
18. Dehydrogenase/reductase SDR family member 2 silencing sensitizes an oxaliplatin‑resistant cell line to oxaliplatin by inhibiting excision repair cross‑complementing group 1 protein expression.
Li JM; Jiang GM; Zhao L; Yang F; Yuan WQ; Wang H; Luo YQ
Oncol Rep; 2019 Nov; 42(5):1725-1734. PubMed ID: 31436301
[TBL] [Abstract][Full Text] [Related]
19. Metabolic consequences of treatment with AKT inhibitor perifosine in breast cancer cells.
Su JS; Woods SM; Ronen SM
NMR Biomed; 2012 Feb; 25(2):379-88. PubMed ID: 22253088
[TBL] [Abstract][Full Text] [Related]
20. Reciprocal regulation of the cholinic phenotype and epithelial-mesenchymal transition in glioblastoma cells.
Koch K; Hartmann R; Schröter F; Suwala AK; Maciaczyk D; Krüger AC; Willbold D; Kahlert UD; Maciaczyk J
Oncotarget; 2016 Nov; 7(45):73414-73431. PubMed ID: 27705917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
